Preludedx
Nashville, US · 3 known investors
Find your way into Preludedx
PreludeDx develops precision diagnostic tests for breast cancer to help physicians make informed treatment decisions and improve patient outcomes. The company serves oncologists, breast surgeons, and pathologists requiring molecular diagnostics for DCIS and other breast cancer subtypes.
Founders & leadership
TB
Troy BremerCo-founder & Chief Scientific Officer
DF
Daniel ForchePresident & CEO
Investors · 3
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $273.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Preludedx do?
- PreludeDx develops precision diagnostic tests for breast cancer to help physicians make informed treatment decisions and improve patient outcomes. The company serves oncologists, breast surgeons, and pathologists requiring molecular diagnostics for DCIS and other breast cancer subtypes.
- Who founded Preludedx?
- Preludedx was founded by Troy Bremer.
- Who are Preludedx's investors?
- Preludedx's investors include Fjord Ventures, BlueStone Venture Partners, Evidity Health Capital.
- Where is Preludedx headquartered?
- Preludedx is headquartered in Nashville, US.